Literature DB >> 32337726

Gepants.

Deborah Tepper1.   

Abstract

Year:  2020        PMID： 32337726     DOI： 10.1111/head.13791

Source DB:  PubMed          Journal:  Headache        ISSN： 0017-8748            Impact factor:   5.887


× No keyword cloud information.
  5 in total

1.  Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series.

Authors:  Tahlia Toni; Rayce Tamanaha; Bashak Newman; Yutong Liang; James Lee; Enrique Carrazana; Vimala Vajjala; Jason Viereck; Kore Kai Liow
Journal:  Neurol Sci       Date:  2021-08-18       Impact factor: 3.307

Review 2.  Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.

Authors:  Fred Cohen; Hsiangkuo Yuan; Stephen D Silberstein
Journal:  BioDrugs       Date:  2022-04-27       Impact factor: 7.744

3.  The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.

Authors:  Xinyu Tao; Zeya Yan; Jiahao Meng; Wei Wang; Qiling Dai; Qiufeng Zhou; Zhifeng Wang; Zhong Wang
Journal:  J Headache Pain       Date:  2022-01-29       Impact factor: 7.277

Review 4.  Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations.

Authors:  Fred Cohen; Hsiangkuo Yuan
Journal:  Ther Clin Risk Manag       Date:  2022-04-22       Impact factor: 2.755

Review 5.  Management of Chronic Migraine in Children and Adolescents: Where are We in 2022?

Authors:  Robert C Gibler; Kaelynn E Knestrick; Brooke L Reidy; Daniel N Lax; Scott W Powers
Journal:  Pediatric Health Med Ther       Date:  2022-09-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.